Vall d’Hebron successfully treats pregnant women with breast cancer • In 2006, the Breast Cancer Unit at the Vall d’Hebron…
Results from Vall d´Hebron´s High Risk and Cancer Prevention Unit (UARPC) recently presented at the European Society of Medical Oncology (ESMO) Congress 2012 (Vienna, 28 September – 02 October) show that the high percentage of premalignant lesions detected in different organs in these adolescents and young people not only justifies these programmes but makes them indispensable.
• The team will be coordinating a study that aims to investigate whether the BKM120 drug can be regarded as…
Nature Medicine´s Senior Editor, Victoria Aranda, will come to VHIO Monday 17 September 2012 to deliver the 4th in the…
New Herceptin® delivery method could vastly simplify breast cancer treatment A new method of delivering a commonly used breast cancer…
In two recent interviews with ecancer Josep Tabernero highlights key studies and promising data presented at the ESMO 14th World Congress on Gastrointestinal Cancer (WCGC), Barcelona, 27 – 30 June 2012, as well as discusses the WIN Consortium (Worldwide Innovative Networking in personalized cancer medicine) launch of WINTHER: The WIN therapeutics clinical trial.
On 12 July 2012, internationally renowned experts in renal carcinoma, Dr. Brian Rini and Dr. Jorge García from the Cleveland…
Nature Medicine´s Senior Editor, Vicotria Aranda will come to VHIO Monday 17 September 2012 to deliver the 4th in the prestigious series of VHIO Meet the Editors talks.
ASCO Annual Meeting 2012: Largest study on women with breast cancer treated with PI3K inhibitors.
– The study was presented at the annual meeting of ASCO (American Society of Clinical Oncology) revealing findings surrounding the largest sample of breast cancer patients treated with this group of drugs.
– This research presented at ASCO was honored through a Merit Award from the Conquer Cancer Foundation — testament to its high quality and important scientific interest.
21 May 2012, Barcelona – Héctor G. Palmer, Principal Investigator of the Stem Cells and Cancer Group at the Vall…
The Vall d’Hebron Institute of Oncology (VHIO) identifies biomarkers that predict resistance to treatment which will enable a better selection of patients who stand to benefit as well as avoid the administration of ineffective medicines.
These findings identify experimental drugs to overcome resistance and open new therapeutic avenues in combinatorial treatment.
CALL FOR APPLICATIONS 2012 The objective of the Fellowship is to provide support to two outstanding MD’s, PhD’s, or MD/PhD’s…
